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Objectives: Observational studies suggest an association 
between vitamin D deficiency and adverse outcomes of critical 
illness and identify it as a potential risk factor for the development 
of lung injury. To determine whether preoperative administration of 
oral high-dose cholecalciferol ameliorates early acute lung injury 
postoperatively in adults undergoing elective esophagectomy.
Design: A double-blind, randomized, placebo-controlled trial.
Setting: Three large U.K. university hospitals.
Patients: Seventy-nine adult patients undergoing elective esopha-
gectomy were randomized.
Interventions: A single oral preoperative (3–14 d) dose of 7.5 mg 
(300,000 IU; 15 mL) cholecalciferol or matched placebo.
Measurements and Main Results: Primary outcome was change 
in extravascular lung water index at the end of esophagectomy. 
Secondary outcomes included Pao2:Fio2 ratio, development of 
lung injury, ventilator and organ-failure free days, 28 and 90 
day survival, safety of cholecalciferol supplementation, plasma 
vitamin D status (25(OH)D, 1,25(OH)2D, and vitamin D-bind-
ing protein), pulmonary vascular permeability index, and extra-
vascular lung water index day 1 postoperatively. An exploratory 
study measured biomarkers of alveolar-capillary inflammation 
and injury. Forty patients were randomized to cholecalciferol 
and 39 to placebo. There was no significant change in extra-
vascular lung water index at the end of the operation between 
treatment groups (placebo median 1.0 [interquartile range, 
0.4–1.8] vs cholecalciferol median 0.4 mL/kg [interquartile 
range, 0.4–1.2 mL/kg]; p = 0.059). Median pulmonary vascular 
permeability index values were significantly lower in the cholecal-
ciferol treatment group (placebo 0.4 [interquartile range, 0–0.7] 
vs cholecalciferol 0.1 [interquartile range, –0.15 to –0.35]; 
p = 0.027). Cholecalciferol treatment effectively increased 
25(OH)D concentrations, but surgery resulted in a decrease in 
25(OH)D concentrations at day 3 in both arms. There was no 
difference in clinical outcomes.
Conclusions: High-dose preoperative treatment with oral cholecal-
ciferol was effective at increasing 25(OH)D concentrations and 
reduced changes in postoperative pulmonary vascular permeability DOI: 10.1097/CCM.0000000000003405
*See also p. 2064.
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Prevention of the acute respiratory distress syndrome (ARDS) has become a focus of research in recent years, with the development of prediction scores (1), preven-
tion trials (2, 3) and a growing evidence of other potential bio-
logical therapies to prevent ARDS (4).
ARDS is common after esophagectomy with studies report-
ing a frequency between 13% and 30% (2, 5–7). During open 
surgery, access to the esophagus is attained by deflation of one 
lung and maintenance of one-lung ventilation (OLV) exposing 
the ventilated lung to volutrauma, hyperoxia, and barotrauma 
(8, 9). Concurrently the deflated lung is exposed to ischemia-
reperfusion injury (10). The pathophysiologic changes of lung 
injury post esophagectomy are similar but less exaggerated 
than in ARDS patients (11–13). This high-risk population has 
been validated for assessing potential therapies to assess bio-
logical efficacy and prevent ARDS (2).
Vitamin D (VD) deficiency is common (14). VD has impor-
tant functions besides bone, and calcium homeostasis and its 
immunomodulatory actions may play a role in the pathogen-
esis of ARDS (15). Studies report a high prevalence of VD defi-
ciency (VDD) in the critically ill (16) with an association with 
increased rates of infection (17, 18) acute respiratory failure 
(19), acute kidney failure (20), sepsis (18, 21), and mortality in 
some (22), but not all studies (23, 24).
We have previously reported severe VDD in a cohort of 
ARDS patients (25). VDD (plasma 25(OH)D < 50 nmol/L) was 
ubiquitous in ARDS patients and present in the vast majority 
of patients at risk of developing ARDS following esophagec-
tomy. Experimental studies suggest a protective effect of VD in 
the lung. In a murine model of intratracheal lipopolysaccharide 
challenge, dietary-induced VDD resulted in exaggerated alveolar 
inflammation, epithelial damage, and hypoxia which were abro-
gated by cholecalciferol treatment (21). In vitro, 25(OH)D has 
trophic effects on primary human alveolar type II cells affecting 
over 600 genes (25). We conducted a phase 2 randomized, pla-
cebo-controlled trial to test our hypothesis that high-dose cho-
lecalciferol treatment preoperatively reduces markers of alveolar 
epithelial lung injury seen post esophagectomy, a high-risk pop-
ulation of developing ARDS. Results of these studies have been 
previously reported in the form of an abstract (26).
MATERIALS AND METHODS
Study Design
A randomized, double-blind placebo-controlled trial, 
recruited patients from October 3, 2012, to January 26, 2015, 
at three hospitals in the United Kingdom. Ethics approval 
was obtained from South Birmingham Research Ethics Com-
mittee (REC 12/WM/0092). Trial registration identification 
ISRCTN27673620 and EudraCT 2012-000332-25. The study 
protocol has been previously published (27). Detailed methods 
can be found in the online supplemental material (Supple-
mental Digital Content 1, http://links.lww.com/CCM/D967).
Eligibility Criteria
Patients undergoing a planned thoracic esophagectomy and 18 
years old or older if male, aged 55 or more than 2 years since 
menopause if female and were able to give written informed 
consent. Exclusion criteria detailed in the online supplemen-
tal material (Supplemental Digital Content 1, http://links.lww.
com/CCM/D967).
Drug Randomization and Masking
The trial drug manufacturer, Novalabs (Leicester, United King-
dom), produced computer-generated randomization sequence 
using a block size of 10 with equal allocation between active and 
placebo groups. Pharmacy, research staff, clinical teams, and 
patients were masked to randomization and treatment allocation.
Drug Administration
Participants received either a single dose of drug (oral cho-
lecalciferol oily solution Vigantol (Novalabs), 300,000 IU 
[7.5 mg; 15 mL]) or matched placebo (Miglyol 812 oil, the 
vehicle for cholecalciferol in Vigantol) 3–14 days prior to 
planned esophagectomy.
Primary Outcome
Primary outcome was change in extravascular lung water index 
(EVLWI) measured by Pulse Contour Continuous Cardiac 
Output (PiCCO
2
) thermodilution catheter (Pulsion Medical 
Systems, Feldkirchen, Germany) at the end of the esophagec-
tomy (measured within 1 hr postoperatively). PiCCO
2
 EVLWI 
has been shown to be a marker for developing lung injury (28) 
and mortality in ARDS (29, 30) and has been used as the pri-
mary outcome in clinical trials in ARDS (31, 32) as well as post 
thoracotomy (33).
Secondary Outcomes
Prespecified trial secondary outcomes were Pao
2
:Fio
2
 ratio, 
development of lung injury in the first 28 days as defined by the 
Berlin Criteria, ventilator and organ failure free days, 28 and 90 
day survival and safety (e.g., hypercalcemia), and tolerability of 
cholecalciferol supplementation. Plasma VD status (25(OH)D, 
1,25(OH)
2
D, and vitamin D binding protein DBP) predrug dose, 
preoperatively, postoperatively, and day 3 as well as EVLWI day 
1 postoperatively (measured at 9 am on day 1). PiCCO
2
 derived 
pulmonary vascular permeability index (PVPI) was added as an 
outcome measure prior to the conduct of the study as recent 
data suggest it was a better measure of alveolar-capillary perme-
ability to differentiate nonhydrostatic edema than EVLWI (34).
Exploratory Outcomes
Details are available in the online supplemental material 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
D967).
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Lung Water Measurements
EVLWI and PVPI were measured by thermodilution (PiCCO
2
) 
as previously described (35, 36). Specified time points for 
measurement were immediately preoperatively, within 1 hour 
postoperatively and day 1 postoperatively (8–9 am). Detailed 
methods are provided in the online supplemental material 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
D967) and published trial protocol (27).
Perioperative Care
Patients underwent a two-stage 
transthoracic esophagectomy 
which included a laparoscopic 
abdominal stage followed by 
an open thoracotomy or mini-
mally invasive technique with 
thoracoscopy. All approaches 
required OLV. Anesthesia was 
performed dependent on the 
anesthetists preferred practice. 
Teams were briefed to adopt a 
lower tidal volume and fluid-
conservative hemodynamic 
management approach.
Sample Size
The trial was powered to detect 
a change of 20% in EVLWI 
with a power of 80% requir-
ing 34 patients (68 in total) in 
each arm to reach the primary 
endpoint (two-tailed p = 0.05). 
An additional six patients were 
added to allow for dropouts, 
such as open/close cases, unex-
pected deaths, and other dif-
ficulties with data collection. 
Detailed information about 
the sample size estimate is pro-
vided in the trial protocol (27).
Statistical Analysis
Data were analyzed using Graph-
pad PRISM 6 software package 
(Graphpad, San Diego, CA). All 
analysis was based on Intention 
to treat. Continuous data were 
assessed for normality using 
the Shapiro-Wilks test and the 
appropriate parametric or non-
parametric test applied. Statisti-
cal significance was predefined 
as two-tailed p value of less than 
0.05. To assess the significance 
of differences between two sets 
of continuous data the unpaired 
t test was used for parametric data, whereas the Mann-Whitney 
U test was used for nonparametric data, except paired data which 
were assessed using paired t test (parametric) or Wilcoxon signed 
rank test (nonparametric). Categorical data were assessed using 
Fisher exact test and chi-square test for larger samples.
RESULTS
Enrollment and Patient Characteristics
A total of 79 patients were enrolled in the study (Consolidated 
Standard of Reporting Trials) (Fig. 1). Eleven patients (14%) did 
Figure 1. Patient Consolidated Standard of Reporting Trials flow diagram. IU = international unit,  
PiCCO = Pulse Contour Continuous Cardiac Output.
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not receive OLV, or it was not possible to measure the primary 
endpoint (EVLWI at the end of surgery). Thirty-five patients 
in the placebo arm and 33 in the cholecalciferol arm (n = 68; 
86%) went on to complete esophagectomy and primary out-
come measurement. All patients (n = 76; 96%) that proceeded 
to surgery were included in the analysis of efficacy and safety 
of cholecalciferol supplementation.
Patient baseline characteristics were well matched (Table 1). 
All procedures were performed for malignancy, and the pre-
dominant cell type was adenocarcinoma. Groups were well 
matched with respect to operative and anesthetic interventions 
(Table 2).
Primary Outcome
There was no difference in the a priori primary outcome of 
change in EVLWI measured within 1 hour postoperatively 
placebo median +1.0 (interquartile range [IQR], 0.4–1.8) ver-
sus cholecalciferol median +0.4 mL/kg (IQR, –0.4 to –1.2 mL/
kg); p value equals to 0.059 (Fig. 2A). There was no difference 
in absolute EVLWI between placebo and cholecalciferol arms 
postoperatively or postoperative day 1 time points (Table E1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
D967). In a within-group analysis, EVLWI rose significantly 
preoperatively to postoperatively only in the placebo group 
(Fig. E1, Supplemental Digital Content 1, http://links.lww.
com/CCM/D967).
Secondary Outcomes
Effects on Perioperative Changes in PVPI. The change in PVPI 
in placebo patients was median 0.4 (IQR, 0–0.7) versus chole-
calciferol median 0.1 (IQR, –0.15 to –0.35); p value equals to 
0.027 (Fig. 2B). There was no difference seen in absolute values 
of PVPI preoperatively, postoperatively, and at day 1 between 
the groups (Table E2, Supplemental Digital Content 1, http://
links.lww.com/CCM/D967). In a within-group analysis PVPI 
significantly increased pre- to postoperatively in patients who 
received placebo, but not VD (Fig. E2, Supplemental Digital 
Content 1, http://links.lww.com/CCM/D967).
Safety of Cholecalciferol Supplementation. Trial medi-
cation was well tolerated with no episodes of hypercalcemia 
TABLE 1. Patient Baseline Characteristics
Patient Characteristics
Placebo,  
n = 39
Cholecalciferol,  
n = 40 p
Age, yr, median (IQR) 66 (58–72) 64.5 (58–70) 0.37
Body mass index, kg/m2, median (IQR) 25.7 (23.6–30.4) 28.2 (24.6–32.5) 0.14
Male, n (%) 31 (79) 36 (90) 0.19
Caucasian, n (%) 36 (92) 40 (100) 0.07
Smoker, n (%)   0.63
 Never 10 (26) 11 (28)  
 Former 24 (63) 20 (51)  
 Current 4 (11) 8 (21)  
 Unknown 1 (2) 1 (3)  
Pack years, median (IQR) 20 (0–40) 15 (0–36) 0.35
Adenocarcinoma, n (%) 32 (82) 35 (88) 0.50
Tumour stage, n (%)   0.34
 0/1 4 (11) 7 (18)  
 2 13 (34) 8 (21)  
 3 22 (55) 25 (62)  
Preoperative chemotherapy, n (%) 33 (84.6) 32 (80.0) 0.77
Lung function
 Forced expiratory volume in 1 sec (% predicted), mean (sd) 105 (17) 104 (16) 0.12
 Forced vital capacity (% predicted), median (IQR) 120 (111–137) 116 (103–125) 0.39
Prerandomization plasma 25(OH)D, nmol/L, median (IQR) 46.4 (37.5–71.5) 47.4 (34.5–68.1) 0.63
Prerandomization plasma 1,25(OH)2D, pmol/L, mean (sd) 98.3 (36.6) 85.0 (33.2) 0.12
Prerandomization plasma DBP, mg/L, median (IQR) 707 (556–1,568) 710 (449–1,079) 0.46
IQR = interquartile range.
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and no reported serious adverse events related to the trial 
medication (detailed in the online supplemental material and 
Table E3, Supplemental Digital Content 1, http://links.lww.
com/CCM/D967).
Efficacy of Cholecalciferol Supplementation Upon VD 
 Status Perioperatively. There was no difference between 
groups in baseline 25(OH)D, 1,25(OH)
2
D, or DBP levels 
(Table 1). A single bolus dose of 300,000 IU of cholecalciferol 
resulted in significant increases in plasma 25(OH)D concen-
tration (Table 3).
On the day of operation 58% of patients who received pla-
cebo were deficient (25(OH)D concentrations < 50 nmol/L) 
compared with 5% of patients who had received the cholecal-
ciferol single bolus dose (χ2 [1, n = 76] =22.36; p < 0.0001).
1,25(OH)
2
D concentrations increased significantly in 
patients randomized to receive cholecalciferol (Table 3) 
although this did not result in significantly different 
1,25(OH)
2
D levels between groups. There was no significant 
change in plasma DBP concentrations.
Following the surgical insult concentrations of 25(OH)D 
and DBP decreased in both groups, but there were persistently 
higher 25(OH)D concentrations in the cholecalciferol treated 
arm day 3 postoperatively (Table 3). This meant that in the 
placebo group VDD was present in 58% on the day of opera-
tion and 90% by day 3. For the cholecalciferol supplemented 
patients, 5% were deficient at the time of operation increasing 
to 49% by day 3 postoperatively, demonstrating that critical ill-
ness induces VDD in this patient group for the first time.
TABLE 2. Anesthetic and Operative Characteristics
Operative Characteristics
Placebo,  
n = 35
Cholecalciferol,  
n = 33 p
Tumor location, n (%)
 Mid esophagus 3 (8.6) 6 (18.2) 0.29
 Esophageal/gastric junction 32 (91.4) 27 (81.8)
Surgical approach, n (%)
 Open 22 (62.9) 22 (66.7) 0.80
 Laparoscopic 13 (37.1) 11 (33.3)
ASA grade, n (%)
 I–II 30 (85.7) 23 (69.7) 0.15
 III–IV 5 (14.3) 10 (30.3)
Duration of one-lung ventilation, min, median (IQR) 151.0 (124.5–196.3) 150.0 (130.0–183.8) 0.82
Duration of surgery, min, mean (sd) 357.4 (69.7) 386.5 (67.2) 0.08
Cumulative fluid balance at end of surgery, L, median (IQR) 2.7 (2–3.7) 3.3 (2.5–4.3) 0.23
Maximum Fio2, median (IQR) 0.85 (0.68–0.9) 0.80 (0.65–0.9) 0.95
Maximum tidal volume, mL/kg predicted body weight, mean (sd) 7.4 (1.5) 7.8 (1.3) 0.34
Positive end-expiratory pressure, cm H2O, mean (sd) 5.29 (2.6) 5.17 (2.2) 0.84
Peak airway pressure, cm H2O, mean (sd) 26.2 (4.3) 26.8 (5.5) 0.64
IQR = interquartile range.
Figure 2. A, Scatter plot of fold change in extravascular lung water index 
(EVLWI). B, Scatter plot of fold change in pulmonary vascular permeability 
index (PVPI). Fold changes shown from pre- to postoperative and 
preoperative to day 1; black lines and squares dots placebo (n = 35); 
gray lines and triangle dots cholecalciferol treatment (n = 33); and data 
presented as medians and interquartile ranges. p values represent Mann-
Whitney U test.
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Clinical Outcomes. There was no significant difference seen 
in Pao
2
:Fio
2
 ratio between the groups. There was no difference 
in ARDS rates between placebo and cholecalciferol treatment 
arms (placebo 4 [11%] of 35 compared with cholecalciferol 4 
[12%] of 33; odds ratio, 0.94; 95% CI, 0.21–4.09). There was 
no difference seen in ventilator-free and organ failure free days 
or survival (28 or 90 d) (detailed in the online supplemental 
material, Supplemental Digital Content 1, http://links.lww.
com/CCM/D967; and Table E4, Supplemental Digital Content 
1, http://links.lww.com/CCM/D967). No patients developed 
renal or cardiac failure in the first 7 days.
Exploratory Outcomes. Details can be viewed in Table E5 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
D967).
Exploratory Post Hoc Analysis of EVLWI and PVPI Mea-
surements. Only 58 % of placebo-treated and 5% of cholecal-
ciferol treated patients were VDD on the day of the operation. 
Therefore a post hoc exploratory-pooled analysis of all patients 
irrespective of treatment arm was performed to determine if 
there is a threshold effect above which the beneficial effects of 
25(OH)D on EVLWI and PVPI are seen. VD sufficient patients 
(> 50 nmol/L) on the day of operation had significantly lower 
increases in EVLWI and PVPI compared with those who were 
deficient irrespective of treatment allocation (Fig. E3, Supple-
mental Digital Content 1, http://links.lww.com/CCM/D967).
DISCUSSION
In this phase 2 biological efficacy study, we sought to deter-
mine if high-dose cholecalciferol replacement attenuates the 
increase in alveolar-capillary permeability and development 
of pulmonary edema after esophagectomy. The main find-
ing was that 300,000 IU of oral cholecalciferol treatment 
 pre-esophagectomy did not reduce the change in EVLWI 
postoperatively but did reduce the change in PVPI.
Vitamin D3, or cholecalciferol, is mainly formed in the skin 
after exposure to sunlight (ultraviolet B). Synthesized or dietary 
VD is hydroxylated in the liver by CYP27A1, CYP2R1, and 
CYP3A4 to 25-hydroxyvitamin D
3
 [25(OH)D] the major circu-
lating form of VD which is widely accepted as the key measure 
of VD status (37). In humans, 25(OH)D is bound to its binding 
protein (DBP) and requires hydroxylation to the active 1,25-dihy-
droxyvitamin D
3
 [1,25(OH)
2
D] by the mitochondrial enzyme 
CYP27B1 (37) in order to activate the VD receptor (VDR) which 
mediates the biological actions of 1,25(OH)
2
D. Both CYP27B1 
and VDR are expressed by cells of the innate and adaptive 
immune system as well as alveolar epithelial cells (38, 39).
Our hypothesis was based upon experimental data: alveolar 
epithelial cells possess the ability to convert circulating 25(OH)
D to active 1,25(OH)
2
D and activate VDR responsive genes (39), 
suggesting organ-specific effects. Physiologically relevant doses 
of 25(OH)D stimulate wound repair, cellular proliferation, and 
reduce soluble Fas ligand induced cell death of human type 2 
alveolar epithelial cells in vitro (25), suggesting that cholecalciferol 
has a direct protective role on the alveolar epithelium. There may 
also be a protective mechanism on the pulmonary endothelium as 
1,25(OH)
2
D has been shown to decrease expression of intercellu-
lar adhesion molecule-1 and prevent neutrophil adhesion, migra-
tion and therefore potentially the initiation of lung injury (40). 
Furthermore, observational studies have found that VDD is com-
mon in patients with sepsis and ARDS and an increased risk of 
developing ARDS in patients undergoing esophagectomy (21, 25).
The changes in PVPI and EVLWI, we observed in this study 
were smaller than the observational studies led us to expect. 
This may reflect a change in baseline VD status in the pop-
ulation studied, which were not as deficient as the patient 
cohort that this study was powered on—median 25(OH)D 
25.5 nmol/L (25) compared with 43.2 nmol/L in the current 
study, suggesting that the beneficial effects of replacement 
may be greater in those with more severe VDD. Additionally, 
improved surgical technique and anesthetic management may 
also explain the smaller postoperative increases in EVLWI and 
PVPI between the two studies that were 5 years apart.
TABLE 3. Perioperative Change in Vitamin D Status
Vitamin D Analysis
Placebo Cholecalciferol
Baseline,  
n = 38
Preoperative, 
n = 38
Postoperative 
Day 3,  
n = 29
Baseline,  
n = 38
Preoperative,  
n = 38
Postoperativep  
Day 3,  
n = 23
25(OH)D (nmol/L), 
median (IQR)
46.3  
(35.4–69.0)
42.7  
(32.4–58.5)
28.0a  
(19.4–40.4)
47.4  
(32.0–67.8)
74.8b,c  
(63.4–92.6)
54.9a,c  
(43.3–69.4)
1,25(OH)2D (pmol/L), 
mean (sd)
98.3 (36.6) 91.9 (32.4) 68.2a (33.5) 85.0 (33.2) 104.9b (36.9) 92.8d (51.2)
Vitamin D binding 
protein (mg/mL), 
median (IQR)
706  
(556–1,568)
685  
(432–1,053)
442a  
(269–694)
710  
(449–1,078)
725  
(506–1,055)
642e  
(380–999)
IQR = interquartile range.
a p < 0.005 preoperative vs postoperative day 3 concentration.
b p < 0.005 baseline vs preoperative concentration, where baseline is pretreatment concentration.
c p < 0.005 placebo vs cholecalciferol for that time point.
d p < 0.05 placebo vs cholecalciferol for that time point.
e p < 0.05 preoperative vs postoperative day 3 concentration.
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High-dose cholecalciferol successfully increased 25(OH)D 
concentrations above sufficiency (50 nmol/L) in 94.7% of cases 
leading to a corresponding and sustained rise in 1,25(OH)
2
D 
level perioperatively. However, following surgical trauma 
induced by esophagectomy, both arms had significant falls in 
25(OH)D day 3 postoperatively demonstrating that critical 
illness can rapidly induce a state of 25(OH)D deficiency. The 
placebo group also saw similar falls in circulating 1,25(OH)
2
D 
perioperatively but not in the patients who received chole-
calciferol, indicating that patients in the placebo group have 
insufficient circulating 25(OH)D to maintain plasma concen-
trations of 1,25(OH)
2
D in the perioperative period.
It is unclear how critical illness promotes this rapid fall, but 
our data suggest that perioperative falls in circulating DBP, the 
major carrier protein produced by the liver may be important. 
Although this could be accounted for by hemodilution (41), 
the cause of loss of binding proteins in acute inflammation is 
still unknown and could also be related to interstitial extrava-
sation from increased vascular permeability following inflam-
matory responses and decreased hepatic synthesis (42). In 
addition, enhanced induction of activation to 1,25(OH)
2
D or 
catabolic pathways such as the formation of 24-hydroxylated 
or three epimer forms of VD that have recently been identified 
may also play a role (43).
There is also evidence that VD may be a negative acute-
phase reactant postelective knee arthroscopy (44) and in acute 
pancreatitis in which it recovers without supplementation 
(45). We believe this is an important area for future research as 
it is critical to inform dosing regimens for further studies into 
rapid VD replacement in critically ill patients. Patients may 
require repeat dosing rather than the large single doses so far 
investigated and serum 25(OH)D may be an unreliable marker 
of VD status after an acute inflammatory insult (46).
Importantly high-dose cholecalciferol therapy was well tol-
erated with no frequency of hypercalcemia. The frequency of 
ARDS in this cohort was 11.7%. Cholecalciferol treatment did 
not prevent the development of ARDS, and there was no dif-
ference in other clinical outcomes, although our study was not 
powered to detect differences in clinical outcomes.
This study has limitations. The changes observed in PVPI 
and EVLWI were much lower than previously observed pos-
sibly due to the current cohort being very much less VD defi-
cient than previously with significant numbers of patients 
in the control arm not being VD deficient. The lower than 
expected PiCCO changes and low frequency of ARDS may have 
led to a type II error with no difference seen in the primary 
outcome. The timing of the dose was not uniform, but this did 
not impact the level of sufficiency in the VD group on the day 
of operation. Our primary outcome was a measure of potential 
in vivo efficacy of VD on the lung barrier, but measurements of 
PiCCO EVLWI have limitations of under- and over-estimation 
due to positive end-expiratory pressure, changes in pulmonary 
vascular occlusion, heterogeneous lung injury, and operator-
dependency (30). Finally, recent studies suggest that higher 
doses than we used and alternative routes of administration 
may be more efficacious in critical illness (47) and sepsis (48), 
but none have investigated effects on lung injury. Our results 
also support the hypothesis of benefit in the more deficient 
cohort and the use of a follow-up maintenance dose which 
we did not use. Clearly, the optimum dose of VD, best route 
of administration, complex metabolic pathways, and multiple 
isoforms that influence its bioactivity need to be established 
in sepsis, ARDS, and critical illness before large-scale trials are 
undertaken.
CONCLUSIONS
A single preoperative dose of cholecalciferol did not reduce 
EVLWI in the human esophagectomy model of lung injury. 
There was some effect on PVPI. Surgical insult results in a pre-
cipitous decrease in VD concentrations, which is an important 
consideration for future trial design to address clinical efficacy 
of VD therapy in ARDS and critical illness. It is clear that the 
ability to rapidly identify critically ill patients who are defi-
cient in VD is a necessary precursor to trial enrollment of VD 
replacement in critically ill patients.
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